华仁药业(300110) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net profit of -48,000 to -36,000 thousand yuan for the fiscal year 2025, representing a year-on-year improvement of 64.92% to 73.69% from the previous year's loss of 136,847.90 thousand yuan[3] - The net profit after deducting non-recurring gains and losses is projected to be -49,000 to -37,000 thousand yuan, with a year-on-year increase of 64.45% to 73.15% compared to last year's loss of 137,819.20 thousand yuan[3] - The company expects to achieve a net profit of 6,000 to 8,000 thousand yuan for 2025, excluding the impact of goodwill impairment[6] Factors Affecting Profitability - The decrease in net profit is primarily due to the absence of significant credit impairment losses from receivables in the current period, which affected the previous year's loss base[5] - The sales prices of some products have decreased due to drug pricing policies, impacting gross margins, but the company's operational fundamentals remain stable[6] - The company anticipates goodwill impairment of 440,000 to 540,000 thousand yuan due to underperformance of subsidiaries, which will be finalized after assessment and audit[5] Strategic Plans - The company plans to enhance production capacity, expand sales channels, and develop new products to improve profitability and sustainable development[6] Legal and Financial Uncertainties - There is significant uncertainty regarding ongoing litigation related to equity transfer disputes involving a subsidiary, which may affect future financial data[7] - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited[7]